Non -Interventional Study-Palliative Therapy of Multiple Myeloma With a Combination of Lenalidomide and Dexamethasone
NCT00911105 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 101
Last updated 2018-06-06
Summary
Purpose of this non-interventional study is the documentation of efficacy and safety data of multiple myeloma therapy with a combined treatment of Lenalidomide and Dexamethasone in daily routine practice.
Conditions
Sponsors & Collaborators
-
iOMEDICO AG
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-05-31
- Primary Completion
- 2012-04-30
- Completion
- 2015-11-30
Countries
- Germany
Study Locations
More Related Trials
-
Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus Lenalidomide, Dexamethasone and MLN9708 After Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly-diagnosed Symptomatic Multiple Myeloma
NCT02406144 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacogenomic Study in Myeloma Patients Treated With Melphalan-prednisone-thalidomide or Lenalidomide-dexamethasone
NCT00907452 ·Status: COMPLETED ·Phase: NA
-
A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma
NCT00928486 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Demonstrate Clinical Benefit of Lenalidomide and Dexamethasone
NCT03809780 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma
NCT00420849 ·Status: COMPLETED ·Phase: PHASE3
-
Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma
NCT02697344 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)
NCT01936532 ·Status: COMPLETED ·Phase: PHASE2
-
IFM2009-02-Pomalidomide and Dexamethasone Phase 2 Myeloma
NCT01053949 ·Status: COMPLETED ·Phase: PHASE2
-
Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide
NCT01794039 ·Status: COMPLETED ·Phase: PHASE2
-
A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma
NCT00478777 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM
NCT04009109 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma
NCT05288062 ·Status: TERMINATED ·Phase: PHASE2
-
Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma
NCT00378105 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma
NCT01731886 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and Bortezomib
NCT04243109 ·Status: TERMINATED ·Phase: PHASE2
-
Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
NCT01049945 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma
NCT01593410 ·Status: COMPLETED ·Phase: PHASE2
-
Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
NCT01155583 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma
NCT01850524 ·Status: COMPLETED ·Phase: PHASE3
-
Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma
NCT00966693 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety Study of Lenalidomide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple Myeloma
NCT02692339 ·Status: COMPLETED
-
Lenalidomide and Dexamethasone for Treatment of Patients With Acute Myeloma (Light Chain)-Induced Renal Failure
NCT00902915 ·Status: UNKNOWN ·Phase: PHASE2
-
Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma
NCT00098475 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression
NCT00482261 ·Status: COMPLETED ·Phase: PHASE2
-
Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT00772915 ·Status: COMPLETED ·Phase: PHASE2